A white paper by the Tufts Center for the Study of Drug Development, commissioned by Thermo Fisher Scientific, finds that integrating contract development and manufacturing organizations (CDMOs) with contract research organizations (CROs) can cut oncology drug development timelines by up to 34 months. The acceleration is attributed to reduced clinical trial gaps and improved management of trial phases through single-vendor oversight. Thermo Fisher anticipates the model’s applicability to other drug modalities beyond oncology.